Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Tsay,; Mj, Hsieh; Lee, Chia-Yi; Ss, Wang; Cs, Chen; Hung, Sheng-Che; Lin, Cai; Yang, Shuhao

doi:10.3390/ijerph17010129

Cited by 6 publications

(9 citation statements)

References 45 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FGFR4 rs1966265 changes chemotherapy response in breast cancer [ 62 ], higher risk of oral squamous cell carcinoma susceptibility [ 31 ], initiation of cervical cancer (Taiwanese women) [ 19 ], and higher risk of breast cancer in Chinese women of Heilongjiang province [ 16 ]. FGFR4 rs2011077 TC+CC polymorphism is associated with higher tumor stage, tumor size, and grading in urothelial cell carcinoma [ 21 ]. FGFR4 rs2011077 with the GG genotype also increased the risk of prostate cancer in Japanese population [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

et al. 2020

View full text Add to dashboard Cite

Fibroblast growth factor receptor 4 (FGFR4) is a cell surface receptor tyrosine kinases for FGFs. Several studies have focused on the association between FGFR4 polymorphisms and cancer development. This meta-analysis aimed to estimate the association between FGFR4 rs351855 (Gly388Arg), rs1966265 (Val10Ile), rs7708357, rs2011077, and rs376618 polymorphisms and cancer risk. Eligible studies were identified from electronic databases. All statistical analyses were achieved with the STATA 14.0 software. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) used to quantitatively estimate the association. Overall, no significant association was found between rs351855, rs2011077, and rs376618 polymorphism with the risk of overall cancer. The rs1966265 polymorphism significantly decreased the risk of cancer in recessive (OR=0.87, 95%CI=0.78-0.97, p=0.009, TT vs CT+CC) genetic model. Whereas the rs7708357 polymorphism was positively associated with cancer risk in dominant (OR=1.17, 95%CI=1.02-1.36, p=0.028) genetic model. Stratified analysis revealed that rs351855 variant significantly increased the risk of prostate cancer in heterozygous (OR=1.16, 95%CI=1.02-1.32, p=0.025 AG vs GG), dominant (OR=1.20, 95%CI=1.06-1.35, p=0.004, AG+AA vs GG), and allele (OR=1.22, 95%CI=1.06-1.41, p=0.005, A vs G) genetic models. In summary, the findings of this meta-analysis indicate that rs1966265, rs7708357 and rs351855 polymorphisms are correlated to cancer development. Further well-designed studies are necessary to draw more precise conclusions.

show abstract

Section: Discussionmentioning

confidence: 99%

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The four SNPs investigated, namely rs2011077, rs351855, rs7708357, and rs1966265, in the FGFR4 genome region have been well defined and suggested to be associated with the risk of various cancers susceptibility [ 22 , 23 , 29 , 39 ]. The peripheral blood samples from lung cancer patients were collected for genomic DNA extraction.…”

Section: Methodsmentioning

confidence: 99%

“…Recent studies have focused on the clinical significance of FGFR4 genetic variations [ 10 ]. FGFR4 SNPs have been shown to be significantly associated with poor survival rates and worse prognosis in prostate cancer [ 11 , 12 ], head and neck cancer [ 13 , 14 ], breast cancer [ 15 , 16 , 17 , 18 , 19 ], ovarian cancer [ 20 ], hepatocellular carcinoma [ 21 ], uterine cervical cancer [ 22 ], urothelial cell carcinoma [ 23 ], pituitary tumors [ 24 , 25 ], soft tissue sarcoma [ 26 ], and oral squamous cell carcinoma [ 27 , 28 , 29 ]. However, the effects of FGFR4 SNPs on the risk of lung cancer seem to be controversial.…”

Section: Introductionmentioning

confidence: 99%

FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan

Huang

Yang

et al. 2020

IJERPH

Self Cite

View full text Add to dashboard Cite

Fibroblast growth factor receptor 4 (FGFR4) is involved in multiple physiological and pathological processes. Several genetic variants of FGFR4 have been shown to be associated with tumor progression in many cancers. However, its association, such as genetic variants and expression levels, with lung cancer is controversial. The present study examined the relationship between four single-nucleotide polymorphisms (SNPs; rs2011077 T/C, rs351855 G/A, rs7708357 G/A, and rs1966265 A/G) of FGFR4 and the risk of lung adenocarcinoma with the epidermal growth factor receptor (EGFR) mutation status in a Taiwanese cohort. The results demonstrated that FGFR4 rs2011077 (odds ratio (OR) = 0.348, 95% confidence interval (CI) = 0.136–0.891, p = 0.024), and rs351855 (OR = 0.296, 95% CI = 0.116–0.751, p = 0.008) showed an inverse association with distant metastasis in wild-type EGFR lung adenocarcinoma. Furthermore, a database analysis using The Cancer Genome Atlas revealed that the higher FGFR4 expression level was correlated with poor survival rates in wild-type EGFR lung adenocarcinoma. In conclusion, the data suggest that FGFR4 SNPs may help in identifying patient subgroups at low-risk for tumor metastasis, among carriers of lung adenocarcinoma bearing wild-type EGFR.

show abstract

“…SNPs can exist in various regions of DNA and can affect the production of transcription factors, translation, and gene expression. Recently, the popularity and widespread use of SNP analysis platforms have made the identification of individual SNPs more convenient ( Tsay et al, 2019 ). The SNPs from FGFR4 have been recognized as an essential participant in cancer occurrence and were associated with prognosis in patients.…”

Section: Fgfr4 In Cancermentioning

confidence: 99%

“…The SNPs from FGFR4 have been recognized as an essential participant in cancer occurrence and were associated with prognosis in patients. Examples are FGFR4 rs351855 in HCC ( Sheu et al, 2015 ), FGFR4 SNP rs2011077 with rs1966265 in urothelial cell carcinoma ( Tsay et al, 2019 ), and FGFR4 rs2011077 and rs1966265 in oral squamous cell carcinoma. FGFR4 can alter the production of relative transcript factors, which influences subsequent translation and gene expression ( Su et al, 2018 ) and is directly related to patient survival ( Chou et al, 2017 ).…”

Section: Fgfr4 In Cancermentioning

confidence: 99%

Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer

Liu

Wang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Fibroblast growth factor receptor 4 (FGFR4) is a tyrosine kinase receptor that is a member of the fibroblast growth factor receptor family and is stimulated by highly regulated ligand binding. Excessive expression of the receptor and its ligand, especially FGF19, occurs in many types of cancer. Abnormal FGFR4 production explains these cancer formations, and therefore, this receptor has emerged as a potential target for inhibiting cancer development. This review discusses the diverse mechanisms of oncogenic activation of FGFR4 and highlights some currently available inhibitors targeting FGFR4.

show abstract

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma

Cited by 6 publications

References 45 publications

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer

FGFR4 Gene Polymorphism Reduces the Risk of Distant Metastasis in Lung Adenocarcinoma in Taiwan

Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer

Contact Info

Product

Resources

About